194 related articles for article (PubMed ID: 22302548)
1. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition.
Chételat G; Villemagne VL; Villain N; Jones G; Ellis KA; Ames D; Martins RN; Masters CL; Rowe CC;
Neurology; 2012 Feb; 78(7):477-84. PubMed ID: 22302548
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
[TBL] [Abstract][Full Text] [Related]
3. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
[TBL] [Abstract][Full Text] [Related]
4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
5. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.
Perrotin A; Mormino EC; Madison CM; Hayenga AO; Jagust WJ
Arch Neurol; 2012 Feb; 69(2):223-9. PubMed ID: 22332189
[TBL] [Abstract][Full Text] [Related]
6. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
[TBL] [Abstract][Full Text] [Related]
7. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
[TBL] [Abstract][Full Text] [Related]
8. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
9. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
[TBL] [Abstract][Full Text] [Related]
10. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
[TBL] [Abstract][Full Text] [Related]
11. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
[TBL] [Abstract][Full Text] [Related]
12. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
[TBL] [Abstract][Full Text] [Related]
14. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
[TBL] [Abstract][Full Text] [Related]
15. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
Schöll M; Wall A; Thordardottir S; Ferreira D; Bogdanovic N; Långström B; Almkvist O; Graff C; Nordberg A
Neurology; 2012 Jul; 79(3):229-36. PubMed ID: 22700814
[TBL] [Abstract][Full Text] [Related]
16. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
[TBL] [Abstract][Full Text] [Related]
17. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
Scheinin NM; Aalto S; Koikkalainen J; Lötjönen J; Karrasch M; Kemppainen N; Viitanen M; Någren K; Helin S; Scheinin M; Rinne JO
Neurology; 2009 Oct; 73(15):1186-92. PubMed ID: 19726751
[TBL] [Abstract][Full Text] [Related]
18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
19. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.
Storandt M; Mintun MA; Head D; Morris JC
Arch Neurol; 2009 Dec; 66(12):1476-81. PubMed ID: 20008651
[TBL] [Abstract][Full Text] [Related]
20. Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment.
Matsuyama K; Yamamoto Y; Sora I
Psychogeriatrics; 2020 Sep; 20(5):726-736. PubMed ID: 32767414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
